Kim Bhatt

Kim Bhatt is investigating whether GLP-1 receptor agonists (semaglutide, tirzepatide) that drive dramatic weight loss in obesity also reduce cancer risk and improve cancer outcomes, providing a pharmacological obesity-cancer prevention intervention. Her research has analyzed large real-world databases showing that GLP-1 agonist use in diabetic patients is associated with reduced incidence of multiple obesity-associated cancers including endometrial, colorectal, hepatocellular, and pancreatic cancer. She is leading prospective studies to validate these associations and define the mechanisms of GLP-1-mediated cancer risk reduction. Her work may establish GLP-1 agonists as cancer prevention agents in obese populations.